II. Indications
- Refractory Rheumatoid Arthritis
- Non-Hodgkin's Lymphoma
- ANCA Vasculitis
III. Contraindications
- Do not use with live virus Vaccines
IV. Mechanism
- Monoclonal Antibody to the CD20 Antigen that depletes CD20 positive B Cells
V. Dosing
-
Rheumatoid Arthritis: 1 gram IV every 2 weeks for 2 doses
- Administered with Methylprednisolone 100 mg
- Non-Hodgkin's Lymphoma or ANCA Vasculitis: 375 mg/m2 IV weekly for 4 doses
VI. Adverse Effects
- Severe infusion reactions (follows first infusion within 30-120 minutes)
- Tumor Lysis Syndrome
- Hepatitis B reactivation
- Renal Insufficiency
VII. Monitoring
- PPD before initiating therapy
- Complete Blood Count at initiation of therapy and then periodically after
Images: Related links to external sites (from Bing)
Related Studies
| Definition (NCI_NCI-GLOSS) | A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody. |
| Definition (NCI) | A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04) |
| Definition (PDQ) | A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1702" NCI Thesaurus) |
| Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129) |
| MSH | C092560 |
| SnomedCT | 108809004, 386919002 |
| English | Chimeric Anti-CD20 Antibody, C2B8 Monoclonal Antibody, monoclonal antibody anti-CD20, CD20 antibody, rituximab, rituximab, rituximab (medication), rituximab [Chemical/Ingredient], riTUXimab, Rituximab Biosimilar BI 695500, BI 695500, Rituximab, Rituximab (product), Rituximab (substance), anti-CD20 monoclonal antibody, RITUXIMAB |
| Spanish | rituximab (producto), rituximab (sustancia), rituximab |
